24th week of 2009 patent applcation highlights part 36 |
Patent application number | Title | Published |
20090148375 | Novel Alkali Metal Hafnium Oxide Scintillators - The present invention provides for a composition comprising an inorganic scintillator comprising an alkali metal hafnate, optionally cerium-doped, having the formula A | 2009-06-11 |
20090148376 | METHOD OF PRODUCING FLUOROAPATITE, FLUOROAPATITE, AND ADSORPTION APPARATUS - A method of producing a fluoroapatite is provided. The method comprises preparing a slurry containing a hydroxyapatite which has at least one hydroxyl group, preparing a hydrogen fluoride-containing solution containing a hydrogen fluoride, mixing the hydrogen fluoride-containing solution with the slurry to obtain a mixture to thereby adjust a pH of the mixture in the range of 2.5 to 5, and reacting the hydroxyapatite with the hydrogen fluoride in the mixture in a state that the pH of the mixture is adjusted within the above range to thereby obtain the fluoroapatite by substituting the at least one hydroxyl group of the hydroxyapatite with fluorine atom of the hydrogen fluoride. The method can produce the fluoroapatite having improved acid resistance by reducing an impurity, such as ammonia, derived from a raw material to a low or very low level. Further, a fluoroapatite having high acid resistance is also provided. Furthermore, an adsorption apparatus using such a fluoroapatite is provided. | 2009-06-11 |
20090148377 | Process For Producing Electrode Active Material For Lithium Ion Cell - The present invention relates to a method for preparing a lithium vanadium phosphate material comprising mixing water, lithium dihydrogen phosphate, V | 2009-06-11 |
20090148378 | Apparatus and Delivery of Oxygen - Disclosed are various aspects of an oxygen generator and a method of oxygen generation. In certain embodiments, the oxygen generator comprises a reaction chamber, a humidifier, and a cap assembly. | 2009-06-11 |
20090148379 | SYSTEMS AND METHODS FOR GENERATION OF HYDROGEN PEROXIDE VAPOR - A system according to one embodiment includes a moisture trap for drying air; at least one of a first container and a second container; and a mechanism for at least one of: bubbling dried air from the moisture trap through a hydrogen peroxide solution in the first container for producing a hydrogen peroxide vapor, and passing dried air from the moisture trap into a headspace above a hydrogen peroxide solution in the second container for producing a hydrogen peroxide vapor. A method according one embodiment includes at least one of bubbling dried air through a hydrogen peroxide solution in a container for producing a first hydrogen peroxide vapor, and passing dried air from the moisture trap into a headspace above the hydrogen peroxide solution in a container for producing a second hydrogen peroxide vapor. Additional systems and methods are also presented | 2009-06-11 |
20090148380 | Method for Producing Metal Oxide Particle - There is provided a method for stably producing metal oxide solid solution particle at low temperature, wherein an alkaline zirconia sol is used as a raw material which is mixed with a metal compound, and then dried and fired. Specifically, there is disclosed a method for producing metal oxide particle (A3) such as zirconia particle in which metal oxides are solid-solubilized, comprising: a step (I) for obtaining metal oxide (A2) sol such as zirconia sol containing a precursor of a metal oxide by mixing an alkaline zirconia (A1) sol which is obtained by a method including a step (i) for heating a zirconium salt (B2) at 60-110° C. in an aqueous medium containing a carbonate of quaternary ammonium and a step (ii) for performing a hydrothermal treatment at 110-250° C., with a compound (B1) containing an element selected from a group consisting of the group II and group III elements of the periodic table; and a step (II) for drying the thus-obtained sol and then firing a resultant substance at a temperature of 500-1200° C. | 2009-06-11 |
20090148381 | METHOD FOR TREATMENT OF DRAIN IN HYDROGEN PRODUCTION AND HYDROGEN PRODUCTION SYSTEM - A method for treating drain in hydrogen production includes steps of gasifying in a gasifier ( | 2009-06-11 |
20090148382 | Technetium- and rhenium-bis(heteroaryl) complexes, and methods of use thereof - One aspect of the invention relates to complexes of technetium (Tc) and rhenium (Re) with various heteroaromatic ligands, e.g., quinolinyl and isoquinolinyl ligands, and their use in fluorescence and radioimaging for a variety of clinical diagnostic applications, as well as radiopharmaceuticals for therapeutic applications. Another aspect of the invention relates to quinolinyl and isoquinolinyl ligands that form a portion of the aforementioned complexes. Methods for the preparation of the technetium and rhenium complexes are also described. Another aspect of the invention relates to quinolinyl and isoquinolinyl ligands based on derivatized lysine, alanine and bis-amino acids for conjugation to small peptides by solid phase synthetic methods. Additionally, the invention relates to methods for imaging regions of a mammal using the complexes of the invention. | 2009-06-11 |
20090148383 | Anticoagulation Agent and Uses Thereof - The present invention provides an anticoagulant agent including a first element capable of inhibiting coagulation and a second element capable of targeting an activated platelet wherein upon administration of element directs the first element to the activated platelet. Also provided is a probe for detecting a blood vessel abnormality including (a) a binding element capable of targeting an activated platelet and (b) a label. Applicant has shown that agents and probes directed to activated platelets are useful in the diagnosis and therapy of coagulation disorders. | 2009-06-11 |
20090148384 | FUNCTIONALIZED, SOLID POLYMER NANOPARTICLES COMPRISING EPOTHILONES - The present invention describes polymer nanoparticles with a cationic surface potential, in which both hydrophobic and hydrophilic pharmaceutically active substances can be encapsulated. The hydrophilic and thus water-soluble substances are encapsulated in the particle core by co-precipitation through ionic complexing with a charged polymer. Both therapeutic agents and diagnostic agents can be used as pharmaceutically active substances for encapsulation. The cationic particle surface permits stable, electrostatic surface modification with partially oppositely charged compounds, which can contain target-specific ligands for improving passive and active targeting. | 2009-06-11 |
20090148385 | Ultrasound Contrast Agents For Molecular Imaging - A new type of contrast agent is described, which comprises matrix particles with a plurality of metal nanoparticles as well as the method of imaging therewith. A plurality of metal nanoparticles are encapsulated in a non-proteinaceous biocompatible or biodegradable matrix particle and/or attached to a non-proteinaceous biocompatible or biodegradable matrix particle, the matrix of the matrix particles being selected from the group consisting of a carbohydrate, a lipid, a synthetic polymer, an aqueous liquid, a surfactant and an organic liquid, or a mixture thereof. The matrix particles are biocompatible and/or biodegradable and can be coupled to targeting molecules for targeted visualization. | 2009-06-11 |
20090148386 | ENZYME SUBSTRATE COMPRISING A FUNCTIONAL DYE AND ASSOCIATED TECHNOLOGY AND METHODS - Enzyme substrates and associated technology of the present invention are provided. An enzyme substrate of the invention may comprise a biologically functional fluorescent dye and an enzyme-specific substrate moiety attached in such a way that the functionality of the functional dye is diminished. An enzymatic reaction may cleave at least a portion of the substrate moiety from the enzyme substrate to provide a more functional product dye. This product dye may be nonfluorescent or weakly fluorescent, in general, and relatively fluorescent, in a particular condition, such as when bound to a partner biological molecule or an assembly of partner biological molecules. An enzyme substrate of the present invention may thus be useful in fluorescence detection, and/or in any of a variety of useful applications, such as the detection of enzymatic activity in a cell-free system or in a living cell, the screening of drugs, or the diagnosis of disease. | 2009-06-11 |
20090148387 | Ultrasmall superparamagnetic iron oxide nanoparticles and uses thereof - The present invention provides a biomimetic contrast agent comprising an amine-functionalized iron (II) oxide/iron(III) oxide nanoparticle core a targeting ligand attached to the nanoparticle core via a linker and an inert outer layer of a hydrophilic polymer conjugated to the targeting ligand and imaging methods using the biomimetic contrast agents. Also, provided is a dual functional contrast agent comprising a metal-doped iron (II) oxide/iron(III) oxide nanoparticle core, an inert layer of gold coating the nanoparticle core and a biodegradable cationic polymer linked thereto. The dual functional contrast agent is complexed to a therapeutic gene and when transfected into mesenchymal stem cells comprises a dual contrast agent and gene delivery system. In addition, methods of using the dual functional system are provided. Furthermore, kits comprising the biomimetic contrast agents and the dual contrast agent and gene delivery system are provided. | 2009-06-11 |
20090148388 | Isoindoline Compounds and Methods of Making and Using the Same - The invention encompasses isoindoline compounds, pharmaceutical compositions comprising them, and methods of their use for the treatment, prevention or management of various diseases and disorders. Examples include, but are not limited to, cancer, inflammatory bowel disease and myelodysplastic syndrome. | 2009-06-11 |
20090148389 | INDUCTION OF MUCOSAL TOLERANCE TO ANTIGENS - Induction of tolerance to antigens by mucosal, preferably oral, delivery of the antigen in combination with an immunomodulating compound producing micro-organism is disclosed. More specifically, Foxp3 | 2009-06-11 |
20090148390 | JUCARA AND ACAI FRUIT-BASED DIETARY SUPPLEMENTS - The present invention relates to stable, palatable, freeze-dried, fruit-based dietary supplements. Specifically, the inventions relates to compositions of Açai fruit and Jucara fruit with high antioxidant capability and cyclooxygenase-inhibitory activity, and their uses. The invention further provides for methods of making stable, palatable, freeze-dried, fruit-based dietary supplements from Açai fruit and Jucara fruit. | 2009-06-11 |
20090148391 | SYNERGISTIC ACTIVE PREPARATIONS COMPRISING DIPHENYLMETHANE DERIVATIVES AND FURTHER SKIN AND/OR HAIR LIGHTENING AND/OR SENILE KERATOSIS REDUCING COMPOUNDS - The present invention relates to specific synergistic active skin- and/or hair-lightening and/or senile keratosis-reducing (cosmetic or pharmaceutical) preparations comprising a mixture comprising or consisting of
| 2009-06-11 |
20090148392 | COMPOSITIONS CONTAINING BENEFIT AGENTS PRE-EMULSIFIED USING COLLOIDAL CATIONIC PARTICLES - A cleansing or a surface-conditioning composition comprising a mixture of (i) and (ii) in water: i) a surfactant selected from the group consisting of anionic, non-ionic, zwitterionic, cationic, and mixtures thereof; and ii) a hydrophobic benefit agent in a particulate form having a mean particle size in the range of 1-1,000 micron, and a specific gravity of ≧1, not encapsulated within a film or a capsule-like enclosure, the particulate hydrophobic benefit agent comprising: a) a physically-modified form of the hydrophobic benefit agent; and b) a deposition-aid material bonded to the surface of the physically-modified benefit agent, wherein the bonding between the benefit agent and the deposition-aid material is achieved prior to addition to i), wherein said deposition-aid material is not a surfactant having a weight average molecular weight of less than 5,000 Dalton. | 2009-06-11 |
20090148393 | Multistep Cosmetic Compositions - The present invention relates to a system of cosmetic and dermatological compositions and methods for treating and improving the aesthetic appearance of a biological surface by altering the optical properties of the biological surface, thereby resulting in a natural, flawless appearance. The compositions of the invention may be topically applied to the biological surface, including but not limited to skin, in an amount effective in improving the aesthetic and natural appearance of the biological surface. | 2009-06-11 |
20090148394 | TREATMENT OF CHRONIC ULCEROUS SKIN LESIONS - The invention provides a method of treating a wound (for example, a chronic ulcerous skin lesion) in a human or non-human mammal (particularly a human). The wound is contacted with a topical hydrogel composition comprising a hydrophilic polymer carrying multiple pendant sulphonyl groups, optionally with multiple pendant carboxylic groups, on each polymer molecule. | 2009-06-11 |
20090148395 | BIOMEDICAL FOAM ARTICLES - The present invention relates to biomedical foam articles for the wound sector which are formed by spraying a polymeric dispersion onto a wound. The polymeric dispersion being sprayed onto a wound surface forms a three-dimensional body which conforms to the spatial shape of the wound and which, as well as covering the wound surface, ensures a complete and accurately fitted packing of the wound in the depth dimension as well as the other dimensions. The biomedical foam articles of the present invention are particularly useful for treating chronic wounds. | 2009-06-11 |
20090148396 | BIOCOMPATIBLE BIODEGRADABLE FUMAGILLIN ANALOG CONJUGATES - Fumagillin analog polymer conjugates, methods of making fumagillin analog polymer conjugates, compositions comprising a polymer conjugate of a fumagillin analog, and methods for treating cancer, or treating angiogenic diseases comprising administering to a subject in need thereof an effective amount of a polymer conjugate of a fumagillin analog, are described. Also described are novel fumagillin analogs, methods of making fumagillin analogs, compositions comprising at least one fumagillin analog, and methods for treating cancer, or treating angiogenic diseases comprising administering to a subject in need thereof an effective amount of a fumagillin analog. | 2009-06-11 |
20090148397 | Compositions and Methods of Treatment With Proanthocyanidin Polymer Antidiarrheal Compositions - Pharmaceutical compositions containing a proanthocyanidin polymer composition which are useful for the treatment and prevention of secretory diarrhea are provided. The invention specifically relates to pharmaceutical formulations of a proanthocyanidin polymer composition which has been isolated from a | 2009-06-11 |
20090148398 | Naturally Occurring Volatile Attractant - A bait composition for the control of fire ants based on fact that an ant pyrazine attractant contained therein will attract foraging fire ants and the fire ants will be stimulated by the phagostimulant to eat the bait and distribute active ingredients also contained therein throughout the colony. Furthermore, the bait composition can be used directly or modified as a surveillance composition for monitoring and detecting fire ants based on the fact that a pyrazine attractant contained therein will attract foraging fire ants to a trap containing a fast acting, non-repellent insecticide that keeps attracted workers in the trap as a measure of fire ant presence. | 2009-06-11 |
20090148399 | Controlled release attractant for gravid female mosquitoes - One or a combination of known chemical cues that attract pregnant female mosquitoes to an egg-laying site are embedded in a biodegradable carrier that releases the compound at a generally constant rate for up to a year or longer. The compound is useful for attracting large numbers of mosquito vectors to a site where they and their progeny can be eliminated. | 2009-06-11 |
20090148400 | COMPOSITION OF TUMOUR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE - The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumour immune responses against colorectal cancer. | 2009-06-11 |
20090148401 | METHODS AND COMPOSITIONS FOR NEEDLELESS DELIVERY OF BINDING PARTNERS - The present invention relates, in part, to methods and compositions for needleless delivery of macromolecules to a subject. In one aspect, the methods and compositions involve administering to the subject a delivery construct comprising a carrier construct non-covalently bound to a binding partner, wherein the carrier construct comprises a receptor-binding domain, a transcytosis domain, and a macromolecule to which the binding partner non-covalently binds, wherein the binding partner binds to the macromolecule with a K | 2009-06-11 |
20090148402 | THERAPY OF NON-MALIGNANT DISEASES OR DISORDERS WITH ANTI-ERBB2 ANTIBODIES - The present application describes treatment of non-malignant indications, such as psoriasis, endometriosis, scleroderma, vascular diseases or disorders, respiratory disease, colon polyps or fibroadenoma, with anti-ErbB2 antibodies (e.g. rhuMAb 2C4). | 2009-06-11 |
20090148403 | Interleukin-9 Antagonist Muteins and Their Pharmacological Methods of Use - This invention relates to IL-9 muteins that inhibit the activity of wild-type IL-9, multimers and Fc-fusion constructs of IL-9 proteins, and an efficient method to purify IL-9 proteins produced by eukaryotic cells. Related formulations, dosages and methods of administration thereof for therapeutic purposes are also provided. More particularly, these IL-9 muteins, compositions, and methods provide a treatment option for individuals afflicted with conditions where inhibiting IL-9 mediated immune responses would be beneficial, such as allergy, asthma, chronic obstructive pulmonary disease (emphysema and chronic bronchitis), pulmonary and gastro-intestinal mucus hyperplasia, inflammation, immunological disorders, leukemia, and lymphoma. | 2009-06-11 |
20090148404 | COMPOSITIONS AND METHODS FOR ELIMINATING UNDESIRED SUBPOPULATIONS OF T CELLS IN PATIENTS WITH IMMUNOLOGICAL DEFECTS RELATED TO AUTOIMMUNITY AND ORGAN OR HEMATOPOIETIC STEM CELL TRANSPLANTATION - The present invention relates generally to methods for stimulating T cells, and more particularly, to methods to eliminate undesired (e.g., autoreactive, alloreactive, pathogenic) subpopulations of T cells from a mixed population of T cells, thereby restoring the normal immune repertoire of said T cells. The present invention also relates to compositions of cells, including stimulated T cells having restored immune repertoire and uses thereof. | 2009-06-11 |
20090148405 | INDUCTION OF DENDRITIC CELL DEVELOPMENT WITH MACROPHAGE-COLONY STIMULATING FACTOR (M-CSF) RECEPTOR LIGANDS - A method of inducing dendritic cell (DC) development by administering Macrophage-Colony Stimulating Factor Receptor Ligand is provided. M-CSF receptor ligands induce DCs to differentiate into subtypes, for example plasmacytoid DCs and conventional DCs. Induction with an M-CSF receptor ligand can be achieved in vitro from hematopoietic precursors, such as bone marrow cells, or in vivo. In vitro, M-CSF receptor ligand-derived DCs can be used to produce cytokines and to stimulate other immune response cells. M-CSF receptor ligands can also be used to induce precursor cells removed from an animal to develop into DCs. In addition, these isolated DCs can be exposed to antigens to stimulate a specific immune response when reintroduced into the animal. Treatments for cancers, such as Acute Myeloid Leukemia, and autoimmune diseases such as Systemic Lupus Erythematosus, are also provided in the invention. | 2009-06-11 |
20090148406 | Stable Aqueous Systems Comprising Proteins - An aqueous system comprises a protein and one or more stabilising agents, characterised in that (i) the one or more stabilising agents have ionisable groups capable of exchanging protons with the protein and with the ionised products of water dissociation; (ii) the ionisable groups include first groups that are positively charged when protonated and uncharged when deprotonated, and second groups that are uncharged when protonated and negatively charged when deprotonated; and (v) the pH of the composition is within a range of protein stability that is at least 50% of the maximum stability of the protein with respect to pH. | 2009-06-11 |
20090148407 | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication - The embodiments provide compounds of the general Formulae (I) through general Formula (VIII), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 2009-06-11 |
20090148408 | LACTOBACILLI EXPRESSING BIOLOGICALLY ACTIVE POLYPEPTIDES AND USES THEREOF - The present invention relates to | 2009-06-11 |
20090148409 | CANINE PROBIOTIC BIFIDOBACTERIA GLOBOSUM - According to the invention there is provided a strain of lactic acid bacteria of the species | 2009-06-11 |
20090148410 | CANINE PROBIOTIC BIFIDOBACTERIA PSEUDOLONGUM - According to the invention there is provided a strain of lactic acid bacteria of the species Bifidobacteria | 2009-06-11 |
20090148411 | VIRAL VECTOR-BASED GENE THERAPY METHODS AND COMPOSITIONS - Disclosed are improved VP2-modified recombinant adeno-associated viral (rAAV) vectors, expression systems, and rAAV virions that are fully virulent, yet lack functional VP2 protein expression. Also disclosed are pharmaceutical compositions, virus particles, host cells, and pharmaceutical formulations that comprise these modified vectors useful in the expression of therapeutic proteins, polypeptides, peptides, antisense oligonucleotides and/or ribozymes in the cells and tissues of selected mammals, including, for example, human tissues and host cells. | 2009-06-11 |
20090148412 | METHODS OF USING A CHOLESTEROL-LOWERING PREPARATION, FOOD SUPPLEMENT AND FOODSTUFF - The present invention relates to cholesterol-lowering preparations, in particular to a bacterial preparation for use as a medicament for lowering of the blood cholesterol level. The present invention provides inter alia a preparation of | 2009-06-11 |
20090148413 | Method for treatment of irritable bowel syndrome - A composition and method for treatment for bowel disorders is described. The composition consists of three parts. The first part is a highly purified, insoluble, chemically unmodified fiber from plants which is mixed with an aqueous solution such as water. The second part of the composition is a commercially available probiotic preparation. These commercially probiotic preparations contain large numbers of viable microorganisms of either | 2009-06-11 |
20090148414 | Novel Composition to Improve Gut Health and Animal Performance and Methods of Making the Same - The present invention relates to compositions comprising at least about 8% β-glucans and/or at least about 8% α-fucans, which has a prebiotic effect and act as a replacement for in-feed antibiotics. The present invention also relates to extraction methods to obtain such extracts and various uses for the compositions comprising β-glucans and/or α-fucans. | 2009-06-11 |
20090148415 | Treatment for Chronic Myocardial Infarct - A method of treating chronic post-myocardial infarction including helical needle transendocardial delivery of autologous bone marrow (ABM) mononuclear cells around regions of hypo or akinesia in chronic post-myocardial infarction (MI) patients. The treatment is safe and improves ejection fraction (EF). | 2009-06-11 |
20090148416 | ANGIOGENICALLY INDUCED TRANSPLANTS AND METHODS FOR THEIR USE AND MANUFACTURE - Angiogenically induced transplants and methods for their use and manufacture are disclosed. The angiogenic potential of the transplants is increased by contacting the transplants with donor mesenchymal cells such as hair follicle dermal papilla stem cells. Methods for treating disorders and diseases, such as disorders of the skin and angiopathies, are also disclosed. | 2009-06-11 |
20090148417 | CARBON NANOTUBES SERVING AS STEM CELL SCAFFOLD - The present invention relates to a scaffold for transplanting a stem cell comprising a carbon nanotube without cytotoxicity, and a composition for stem cell therapy comprising (a) a stem cell; and (b) a carbon nanotube serving as a stem cell scaffold without cytotoxicity. The scaffold for transplanting stem cells comprising carbon nanotubes show excellent effects without cytotoxicity on networking between differentiated stem cells and tissues present in transplantation sites, thereby showing significant cell therapy efficacy. | 2009-06-11 |
20090148418 | Skeletal Site-Specific Characterization of Orofacial and Illiac Crest Human Bone Marrow Stromal Cells in Same Individuals - The present invention relates to methods and compositions useful for the detection, enrichment, and use of orofacial-derived bone marrow stromal cells. In one aspect, the invention relates to the use of characteristics specific to orofacial-derived bone marrow stromal cells to distinguish orofacial-derived bone marrow stromal cells from other cells. | 2009-06-11 |
20090148419 | USE OF ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS FOR THE TREATMENT OF GRAFT VERSUS HOST DISEASE - The present invention relates to the use of a particular type of adipose tissue derived mesenchymal stem cells (AD-MSCs), which exert immunosuppressive properties, in the manufacture of a pharmaceutical composition for the prevention and treatment of the graft-versus-host disease (GVHD) produced after allogeneic hematopoietic stem cell transplantation. | 2009-06-11 |
20090148420 | STEM CELLS - Stem cells obtained through in vitro culture with heparan sulphate are described. | 2009-06-11 |
20090148421 | COMPOSITIONS COMPRISING VASCULAR AND MYOCYTE PROGENITOR CELLS AND METHODS OF THEIR USE - The invention provides compositions of adult cardiac vascular progenitor cells (VPCs) and adult cardiac myocyte progenitor cells (MPCs) useful for the treatment of various cardiac conditions. The invention also encompasses methods of generating a biological bypass, repairing damaged myocardium, and treating or preventing hypertensive cardiomyopathy and heart failure with the compositions of the invention. Methods of isolating the cardiac progenitor cells are also disclosed. | 2009-06-11 |
20090148422 | METHODS OF PROLIFERATING STEM CELLS - The invention relates to methods of proliferating stem cells. More particularly, the invention relates to the use of glycosaminoglycans or proteoglycans to promote the growth of stem cells in ex vivo culture, while preserving their multipotentiality. | 2009-06-11 |
20090148423 | ENDOTHELIAL PROGENITOR CELLS AND METHODS OF USE THEREOF - Endothelial progenitor cells immunoreactive for VEGFR-2 or Tie-2, and CD45 are provided. Optionally the cell is immunoreactive with CD14. The cells are capable of differentiating in vivo into an endothelial cell or a smooth muscle cells. The cultures integrate well after transplantation into adult vasculature. | 2009-06-11 |
20090148424 | Reversibly immortalized mammalian liver cells and use thereof - The present invention provides a reversibly immortalized mammalian liver cell line, especially CYNK-1 (deposited with International Patent Organism Depository, National Institute of Advanced Industrial Science and Technology, address: AIST Tsukuba Central 6, 1-1, Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, 305-8566 Japan, deposited date: Mar. 10, 2004, accession number: FERM BP-08657) comprising an immortalizing gene interposed between a pair of site-specific recombination sequences and a suicide gene in the outside of the pair of site-specific recombination sequences, characterized in that the suicide gene can exhibit its function after excision of the pair of site-specific recombination sequences, or passage cell line thereof; a mammalian liver cell obtained by excising the immortalizing gene from the reversibly immortalized mammalian liver cell line or passage cell line thereof; and use of these cells. By utilizing the reversibly immortalized mammalian liver cell line of the present invention enables the obtainment of the number of the liver cells and utilization as materials for artificial liver reactors and cell preparations. | 2009-06-11 |
20090148425 | THERAPEUTIC METHOD FOR BLOOD COAGULATION DISORDER - The present invention provides agents for treating blood coagulation abnormalities, which contain as an active ingredient a lentiviral vector carrying a blood coagulation factor gene operably linked to a promoter which induces platelet-specific expression. Agents for treating hemophilia A or hemophilia B are provided by application of the gene encoding Factor VIII or Factor IX. Blood coagulation abnormalities can be treated by gene therapy by infecting hematopoietic stem cells or such with the therapeutic agents of the present invention. | 2009-06-11 |
20090148426 | COMPOSITION FOR LIFE EXTENSION AND METHOD OF EXTENDING THE LIFE - The present invention relates to a composition for life extension, comprising reduced coenzyme Q | 2009-06-11 |
20090148427 | PLATELET GLYCOPROTEIN IB ALPHA FUSION POLYPEPTIDES AND METHODS OF USE THEREOF - The present invention provides compositions and methods for treating or preventing vascular-associated disorders. | 2009-06-11 |
20090148428 | Glycine N-methyltransferase (GNMT) Animal model and use thereof - The present invention is a new type of Glycine N-methyltransferase (GNMT) knockout mice model. This model can be applied to screen drug, test of treatment and search for diagnostic marker of hepatocellular carcinoma (HCC), glycogen storage disease, liver dysplasia, fatty liver and other liver disease. | 2009-06-11 |
20090148429 | DEBRIDING COMPOSITION FROM BROMELAIN AND METHODS OF PRODUCTION THEREOF - The present invention relates to a debriding composition obtained from bromelain and to methods of producing same. Particularly, the present invention relates to a debriding composition obtained from bromelain comprising proteolytic enzymes having molecular weights of about 23 kDa, being essentially devoid of bromelain inhibitors, and to pharmaceutical compositions comprising same. The debriding compositions and the pharmaceutical compositions comprising same are particularly useful in debriding eschar tissues and in wound healing. | 2009-06-11 |
20090148430 | HUMAN OBESITY SUSCEPTIBILTY GENE ENCODING POTASSIUM ION CHANNELS AND USES THEREOF - The present invention more particularly discloses the identification of human obesity susceptibility genes, which can be used for the diagnosis, prevention and treatment of obesity ant associated disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses certain alleles of potassium voltage-gated channel (E.CNA) genes related to susceptibility to obesity and representing novel targets for therapeutic intervention. More particularly, the potassium volt-age-gated channel (KCNA) genes are located on chromosome 12 and are selected from the group consisting of KCNA1, KCNA5 and KCNA6. The present invention relates to particular mutations in the KCNA1, KCNA5 and KCNA6 genes and their expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of predisposition to, detection, prevention and/or treatment of coronary heart disease and metabolic disorders, including but not limited to hypoalphalipoproteinemia, familial combined hyperlipidemia, insulin resistant syndrome X or multiple metabolic disorder, coronary artery disease, diabetes and associated complications and dyslipidemia. | 2009-06-11 |
20090148431 | MODULATING THE PRODUCTION OF NEURONS AND/OR OLIGODENDROCYTES FROM WHITE MATTER PROGENITOR CELLS - The present invention relates to a method of modulating production of neurons and/or oligodendrocytes from neural progenitor cells of human white matter and to a method of treating a subject for a condition modulated by underproduction of oligodendrocytes from human white matter. Both of these methods involve administering an agonist or antagonist of one or more molecules set forth in Tables 1 and/or 2 to the neural progenitor cells. Also disclosed is a method of using an inhibitor of sterol synthesis to differentiate oligodendrocyte progenitor cells to oligodendrocytes. | 2009-06-11 |
20090148432 | COMPOSITIONS FOR INHIBITING ATHEROSCLEROSIS - The present invention relates to compositions and methods for the reduction of atherosclerotic plaques and the decrease in the level of total serum cholesterol, triglycerides, serum LDL cholesterol, and serum HDL cholesterol. | 2009-06-11 |
20090148433 | METALLO-PROTEIN AND TOCOTRIENOL (MP-T3) COMPOSITIONS AND USES THEREOF - Metallo-proteins including but not limited to lactoferrin (LF), transferrin (TF) and ovotransferrin (OTF) (all members of transferrin family), ceruloplasmin (CP) and metallo-thionein (MT) were found to stabilize and enhance the bio-functional activity of tocotrienol (T3), T3 mixtures or derivates. The synergism between MP and T3 also promote the intestinal transfer and the ultimate bio-availability of T3 and T3-derivatives for physiological functions. Such functional synergism includes hypocholesterolemic, anti-thrombotic, antioxidant, anti-athermogenic, anti-inflammatory and immuno-regulatory activities of T3 agents. These T3 compositions are useful as pharmaceuticals, in cosmetics, in foods and as nutritional supplements. | 2009-06-11 |
20090148434 | Antibody Compositions and Methods - Provided are concentrated preparations comprising single immunoglobulin variable domain polypeptides that bind target antigen with high affinity and are soluble at high concentration, without aggregation or precipitation, providing, for example, for increased storage stability and the ability to administer higher therapeutic doses. | 2009-06-11 |
20090148435 | ANTIBODY PURIFICATION BY CATION EXCHANGE CHROMATOGRAPHY - A method for purifying an antibody by cation exchange chromatography is described in which a high pH wash step is used to remove of contaminants prior to eluting the desired antibody using an elution buffer with increased conductivity. | 2009-06-11 |
20090148436 | ANTIBODY TO GDF8 AND USES THEREOF - The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti-GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8-associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention. | 2009-06-11 |
20090148437 | POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS - The present invention relates to polypeptides e.g. protease resistant polypeptides, immunoglobulin (antibody) single variable domains e.g. which are protease resistant and also to vascular endothelial growth factor (VEGF) antagonists comprising these. The invention further relates to uses, formulations, and compositions comprising such polypeptides e.g. for delivery to the eye. | 2009-06-11 |
20090148438 | Binding Moieties Based on Shark Ignar Domains - The present invention relates to immunoglobulin new antigen receptors (IgNARs) from fish and uses thereof. In particular, the present invention relates to modified IgNAR variable domains and to domains from members of the immunoglobulin superfamily that have been modified to include structural features derived from IgNAR variable domains. | 2009-06-11 |
20090148439 | Methods for diagnosis and treatment of epithelial-derived cancers - The present invention relates to the use of a polypeptide (CD27L) for diagnosis of epithelial-related cancers, in particular kidney cancer e.g. renal cell cancer and colorectal cancer, e.g. colon cancers, as well as in methods of treatment of such cancers. | 2009-06-11 |
20090148440 | ANTIBODIES AGAINST INTERLEUKIN-22 BINDING PROTEIN AND ITS USES FOR THE TREATMENT OF METABOLIC DISORDERS - The present invention relates to antibodies and antigen-binding fragments that bind to interleukin-22 binding protein, in particular, human interleukin-22 binding protein (IL-22 BP), and are involved in regulating interleukin-22-associated biological responses. The invention also relates to methods of using the antibodies and antigen-binding fragments to treat disorders associated with interleukin-22. The antibodies disclosed herein are useful in diagnosing, preventing, or treating metabolic disorders including obesity, diabetes, hyperlipidemia and hyperinsulinemia etc. | 2009-06-11 |
20090148441 | Anti-Cancer Antibodies With Reduced Complement Fixation - The invention provides modified antibodies directed against GD2 that have diminished complement fixation relative to antibody-dependent, cell-mediated cytotoxicity, which is maintained. The modified antibodies of the invention may be used in the treatment of tumors such as neuroblastoma, glioblastoma, melanoma, small-cell lung carcinoma, B-cell lymphoma, renal carcinoma, retinoblastoma, and other cancers of neuroectodermal origin. | 2009-06-11 |
20090148442 | COMBINATION OF BLyS INHIBITION AND ANTI-CD 20 AGENTS FOR TREATMENT OF AUTOIMMUNE DISEASE - The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and anti-CD20 agents for the treatment of autoimmune diseases. One preferred method is where the BLyS antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF—R-Fc-fusion protein comprising the extracellular domain of BAFF—R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of anti-CD20 agents contemplated include RITUXAN®, ocrelizumab, ofatumumab (HuMax-CD20®), TRU-015, and DXL625, although any agent that binds to CD 20 may be suitable. The methods of the present invention reduce the levels of B cells in patients in need of such reduction, such as those suffering from autoimmune diseases. | 2009-06-11 |
20090148443 | HUMANIZED ANTIBODIES AND COMPOSITIONS FOR BINDING SPHINGOSINE-1-PHOSPHATE - The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases and conditions associated with aberrant levels of S1P. | 2009-06-11 |
20090148444 | PHARMACEUTICAL COMPOSITION FOR TREATING IMMUNE DISEASES - An antibody against AILIM (alternatively called JTT-1 antigen, JTT-2 antigen, ICOS and 8F4) was found to have a significant therapeutic effect on arthrosis, for example, rheumatoid arthritis and osteoarthritis, graft versus host disease, graft immune rejection, inflammation (hepatitis and inflammatory bowel diseases), diseased condition accompanied by the excessive production of an antibody against a foreign antigen triggered by immunological sensitization by the antigen. | 2009-06-11 |
20090148445 | METHODS OF SENSITIZING CANCER TO THERAPY-INDUCED CYTOTOXICITY - The present application demonstrates that Salinosporamide A can be used to sensitize cancer cells to cancer therapy. Furthermore, the present application demonstrates that Salinosporamide A acts as a therapeutic agent to kill or inhibit cancer cells after sensitization of the cells by an antibody or other chemosensitizing reagents. The cancer cells can be either therapy-sensitive or therapy resistant. The present application further demonstrates that Salinosporamide A induces the expression of Raf kinase inhibitor protein (RKIP) and PTEN, tumor suppressor proteins, and inhibits the expression of YY1, a transcriptional regulator protein overexpressed in cancer cells and also inhibits the growth factor pleiotrophin (PTN). | 2009-06-11 |
20090148446 | Method and Composition for Treatment of Renal Failure with Antibodies and Their Equivalents as Partial or Complete Replacement for Dialysis - A method for treating renal failure associated with advanced stage renal disease includes administering a soluble cytokine receptor to one or more of tumor necrosis factor alpha, interferon gamma or interleukin 6; or antibodies to one or more of interleukin 6 or interleuking 1 beta. The method can be used as a supplement to or as partial or complete replacement for dialysis. A pharmaceutical composition includes antibody or functional equivalent thereof to urea, creatinine, or both; antibody, functional equivalent or soluble cytokine receptor to tumor necrosis factor alpha, interferon gamma, interleukin 6, interleukin 1 beta or any combination thereof. The composition can be included in a kit. | 2009-06-11 |
20090148447 | Binding Peptides Having a C-terminally Disposed Specific Binding Domain - Specific binding peptides having a general schematized structure of an optional N-terminal hinge region joined to an immunoglobulin-derived constant sub-region comprising a C | 2009-06-11 |
20090148448 | METHODS AND COMPOSITIONS FOR MODULATING AND DETECTING WISP ACTIVITY - Methods and compositions for use in modulating the activity(s) of WISP-1 polypeptide are provided. WISP-1 antagonists include anti-WISP-1 antibodies, WISP-1 immunoadhesins and WISP-1 variants (and fusion proteins thereof) which inhibit or neutralize induction or secretion of HAS2, HA, CD44 or RHAMM by native human WISP-1 polypeptide in at least one type of mammalian cell. The invention also provides methods for in vitro, in situ, and/or in vivo diagnosis and/or treatment of mammalian cells or pathological conditions associated with native WISP-1 polypeptides. | 2009-06-11 |
20090148449 | Antibodies against cd38 for treatment of multiple myeloma - Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies. | 2009-06-11 |
20090148450 | ATF4 As A Therapeutic Target In Alzheimers Disease And Other Neurological Disorders - The present invention relates to methods and compositions for treating Alzheimer's Disease and other neurological disorders by inhibiting expression and/or activity of ATF4. It further provides for diagnostic methods and reagents as well as assays to identify agents for the treatment of Alzheimer's Disease and other ATF4-related conditions. | 2009-06-11 |
20090148451 | Therapeutic anti-cytomegalovirus compounds - The present invention provides synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds, and immune effector cells raised in response to presentation of these epitopes. The invention further provides methods for inducing an immune response and administering immunotherapy to a subject by delivering the compositions of the invention. | 2009-06-11 |
20090148452 | Composition for treating cancer adapted for intra-tumoral administration and uses thereof - A composition is adapted for intra-tumoral administration of a subject suffering from cancer, whereby administration of the composition to the subject induces IMC differentiation by neutralizing a factor implicated in a DC differentiation defect. | 2009-06-11 |
20090148453 | Monoclonal antibodies against HMGB1 - In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample. | 2009-06-11 |
20090148454 | Peptide Domain Required For Interaction Between The Envelope of a Virus Pertaining to The Herv-W Interference Group and an Hasct Receptor - The invention relates to a peptide domain required for interaction between the envelope of a virus pertaining to the HERV-W interference group and a hASCT receptor, comprising an N end point and a C end point. Said peptide domain is defined, at the N end point thereof, by a pattern formed by the amino acids L (Z)-proline-cysteine-X-cysteine in which Z is any amino acid, is a whole number between 2 and 30, and X is any amino acid, and at the C end point thereof, by a pattern formed by the amino acids serine-aspartic acid-Xa-Xb-Xc-Xd-Xe-aspartic acid-Xf-Xg-(Z) in which Xa, Xb, Xc, Xd, Xe, Xf, Xg are any amino acids, Z is any amino acid, B is a whole number between 15 and 25, preferably 20. The peptide domain comprises, between the N end point and the C end point, at least one pattern selected from the following patterns: a pattern formed by the amino acids cysteine-X2-X3-X4-X5-X6-cysteine in which X2, X3, X4, X5, X6 are any amino acids, and a pattern formed by the amino acids cysteine-X7-X8-X9-X10-X11-X12-X13-X14-X15-cysteine-trytophane in which X7, X8, X9, X10, X11, X12, X13, X14, X15 are any amino acids. | 2009-06-11 |
20090148455 | Anti-RANTES antibodies and methods of use thereof - The invention relates to fully human monoclonal antibodies, and fragments thereof, that bind to the chemokine Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES, CCL5), thereby modulating the interaction between RANTES and one of more of its receptors, such as, e.g., CCR1, CCR3, CCR4 and CCR5, and/or modulating the biological activities of RANTES. The invention also relates to the use of these or any anti-RANTES antibodies in the prevention or treatment of immune-related disorders and in the amelioration of one or more symptoms associated with an immune-related disorder. | 2009-06-11 |
20090148456 | CANINE RANKL AND METHODS FOR PREPARING AND USING THE SAME - The present invention provides isolated nucleic acid molecules that encode a substantial part of canine RANKL polypeptide, including the extracellular domains of that polypeptide, the polypeptide and fragments thereof. Vectors and host cells encoding and expressing canine RANKL polypeptide are provided, as well as antibodies that bind to RANKL and that inhibit RANKL activity. Also provided are methods of treating an animal to inhibit or treat the loss of bone minerals. | 2009-06-11 |
20090148457 | HEPATOCYTE GROWTH FACTOR RECEPTOR ANTAGONISTS AND USES THEREOF - Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided. | 2009-06-11 |
20090148458 | COAGULATION FACTOR III POLYMORPHISMS ASSOCIATED WITH PREDICTION OF SUBJECT OUTCOME AND RESPONSE TO THERAPY - The invention provides methods and kits for obtaining a prognosis for a subject having or at risk of developing an inflammatory condition or hypertension. The method generally comprises determining a coagulation factor III genotype(s) of a subject for one or more SNPs, comparing the determined genotype with known genotypes for the polymorphism that correspond with the ability of the subject to recover from the inflammatory condition and identifying subjects based on their prognosis. The invention also provides for methods of identifying potential subjects having an inflammatory condition who are more likely to benefit from treatment with an anti-inflammatory agent or anti-coagulant agent and subsequent to treatment recover from the inflammatory condition. The invention also provides for methods of treating such subjects with an anti-inflammatory agent or anti-coagulant agent based on the subject's genotype. | 2009-06-11 |
20090148459 | Prevention or Treatment of Cancer Using Integrin alphavbeta3 Antagonists in Combination with Other Agents - The present invention relates to methods and compositions designed for the treatment, management or prevention of cancer. The methods of the invention comprise the administration of an effective amount of one or more antagonists of Integrin α | 2009-06-11 |
20090148460 | EXOSOME LIGANDS, THEIR PREPARATION AND USES - The present invention relates to exosome-specific ligands and compositions comprising the same. The invention also relates to methods of generating said ligands and compositions, to methods of using said ligands or compositions, e.g., to block the exosome pathway or to detect and/or characterize exosomes in a sample or subject, as well as to the antigens contacted by said ligands or compositions. The application can be used in experimental, research, therapeutic, prophylactic or diagnostic areas. | 2009-06-11 |
20090148461 | ANTI FGF23 ANTIBODY AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - To provide an antibody against FGF23 and a pharmaceutical composition such as a preventive or therapeutic agent which can prevent or treat by suppressing an action of FGF23 by using the antibody. An antibody or its functional fragment against human FGF23 produced by hybridoma C10 (Accession No. FERM BP-10772). | 2009-06-11 |
20090148462 | METHODS AND COMPOSITIONS FOR USE IN TREATMENT OF PATIENTS WITH AUTOANTIBODY POSITIVE DISEASE - The present invention relates to methods and compositions for use in treatment of patients with autoantibody positive disease. In a specific embodiment, the present invention relates to a method of treating a patient that has an ANA titer of 1:80 or greater and/or greater than or equal to 30 IU/ml of anti-dsDNA antibodies in his/her blood plasma or serum comprising administering a therapeutically effective amount of an immunomodulatory agent, such as an antagonist of Neutrokine-alpha. Additionally provided is a method of reducing the frequency and/or quantity of corticosteroid administration to patients. In preferred embodiments, the patient has systemic lupus erythematosus. Methods for determining if a lupus patient is responding to medical treatment are also provided. | 2009-06-11 |
20090148463 | IVIG MODULATION OF CHEMOKINES FOR TREATMENT OF MULTIPLE SCLEROSIS, ALZHEIMER'S DISEASE, AND PARKINSON'S DISEASE - The present invention provides methods for providing a prognosis of treatment of diseases associated with inflammatory disease of the brain, including MS, e.g., relapsing-remitting multiple sclerosis (RRMS), Alzheimer's disease, and Parkinson's disease using molecular markers that are shown to be overexpressed or underexpressed in patients treated with intravenous immunoglobulins (IVIG). Also provided are methods to identify compounds that are useful for the treatment or prevention of MS, e.g., relapsing-remitting multiple sclerosis (RRMS), Alzheimer's disease, and Parkinson's disease. | 2009-06-11 |
20090148464 | PREVENTIVE OR THERAPEUTIC AGENT CONTAINING ANTI THIOREDOXIN ANTIBODY POLYPEPTIDE AS AN ACTIVE INGREDIENT FOR DISORDERS - The present invention provides a preventive or therapeutic agent being effective for disorders induced by macrophage migration inhibitory factor and vascular system disorders, and having fewer side effects. In particular, the present agent is characterized by containing anti TRX antibody polypeptide as an active ingredient to inhibit adherence of leukocyte to vascular endothelial cell and a cell internalization of the macrophage migration inhibitory factor. | 2009-06-11 |
20090148465 | MUTANTS OF THE P4 PROTEIN OF NONTYPABLE HAEMOPHILUS INFLUENZAE WITH REDUCED ENZYMATIC ACTIVITY - A P4 variant protein that has reduced enzymatic activity and that induces antibody to wild-type P4 protein and/or has good bactericidal activity against non-typable | 2009-06-11 |
20090148466 | Process for the Preparation of Hypoallergenic Mosaic Antigens - A process for the preparation of an hypoallergenic mosaic antigen derived from an allergen is disclosed whereby a) in a first step the allergen is split into at least two parts and the IgE reactivity of each part is determined and b) in a second step those parts of the allergen which have no detectable IgE reaction are combined to a mosaic antigen which comprises the amino acids of the allergen but the order of the amino acids of the mosaic antigen is different from that of the naturally occurring allergen. | 2009-06-11 |
20090148467 | HERPES SIMPLEX VIRUS COMBINED SUBUNIT VACCINES AND METHODS OF USE THEREOF - This invention provides vaccines comprising two or more recombinant Herpes Simplex Virus (HSV) proteins selected from a gD protein, a gC protein and a gE protein; and methods of impeding immune evasion by HSV thereby vaccinating a subject against HSV and treating, suppressing, inhibiting, and/or reducing an incidence of an HSV infection or a symptom or manifestation thereof, comprising administration of a vaccine of the present invention. | 2009-06-11 |
20090148468 | RAPID, EFFICIENT PURIFICATION OF HSV-SPECIFIC T-LYMPHOCYTES AND HSV ANTIGENS IDENTIFIED VIA SAME - Described is a method of identifying an immunologically active antigen of a virus that attacks skin, as well as a method of enriching a population of lymphocytes for T lymphocytes that are specific to a virus that attacks skin. Also provided are HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection that have been identified via the methods of the invention. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection. | 2009-06-11 |
20090148469 | Multicomponent meningococcal vaccine - A composition is provided comprising | 2009-06-11 |
20090148470 | PROTEIN-BASED STREPTOCOCCUS PNEUMONIAE VACCINES - The present invention is primarily directed to a method for preventing infection of a mammalian subject with | 2009-06-11 |
20090148471 | Molecular Vaccine Linking an Endoplasmic Reticulum Chaperone Polypeptide to an Antigen - This invention provides compositions and methods for inducing and enhancing immune responses, such as antigen-specific cytotoxic T lymphocyte (CTL) responses, using chimeric molecules comprising endoplasmic reticulum chaperone polypeptides and antigenic peptides. In particular, the invention provides compositions and methods for enhancing immune responses induced by polypeptides made in vivo by administered nucleic acid, such as naked DNA or expression vectors, encoding the chimeric molecules. The invention provides a method of inhibiting the growth of a tumor in an individual. The invention also provides novel self-replicating RNA virus constructs for enhancing immune responses induced by chimeric polypeptides made in vivo. | 2009-06-11 |
20090148472 | IDENTIFICATION OF PROTECTIVE ANTIGENIC DETERMINANTS OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS AND USES THEREOF - The invention relates to a polypeptide of a protective antigenic determinant (PAD polypeptide) of porcine reproductive and respiratory syndrome virus (PRRSV) and nucleic acids encoding a PAD polypeptide. The PAD polypeptide and nucleic acids encoding a PAD polypeptide are useful in the development of antibodies directed to PAD, vaccines effective in providing protection against PRRSV infection, and diagnostic assays detecting the presence of PAD antibodies generated by a PAD-specific vaccine. The invention also discloses methods of generating antibodies to PAD, for vaccinating a pig to provide protection from PRRSV infections, a method of preparing the vaccine, a method of treating PRRSV infections in a pig, and a method of detecting antibodies to PAD of PRRSV. | 2009-06-11 |
20090148473 | MICROBIAL VACCINE AND VACCINE VECTOR - The present invention includes cold-adapted, acid-fast bacterium for use as a vaccine and a vaccine vector. In preferred embodiments, the cold-adapted, acid-fast bacterium is a | 2009-06-11 |
20090148474 | PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME ISOLATES AND METHODS OF USE - A method of predicting the virulence of a new or uncharacterized PRRS virus isolate is provided wherein the isolate is injected into swine and allowed to replicate for a period of from about 3-15 days. During this period, the rate of virus growth and/or the magnitude of viremia is determined, and this data is compared with a corresponding growth rate and/or viremia magnitude of a PRRS virus isolate of known virulence, as a measure of the virulence of the new or uncharacterized isolate. Additionally, a method of selecting an isolate for inclusion in an immunogenic composition based on the predicted virulence is also provided, together with compositions incorporating attenuated forms of viruses predicted to be virulent. | 2009-06-11 |